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  Statement of the Commission on Narcotic Drugs on the impact of 
the coronavirus disease (COVID-19) pandemic on the 
implementation of Member States’ joint commitments to address 
and counter all aspects of the world drug problem 
 
 
 The Commission on Narcotic Drugs,  
 Adopts the following statement on the impact of the coronavirus disease 




  Statement on the impact of the coronavirus disease (COVID-19) 
pandemic on the implementation of the joint commitments of 




1. The Commission on Narcotic Drugs expresses grave concern about the 
devastating impact of the coronavirus disease (COVID-19) pandemic across the 
world, and pays tribute to the victims, first responders and all other persons whose 
efforts and commitment, often undertaken at great risk to their health and that of their 
families, have contributed to the fight against the pandemic.  
2. The Commission reaffirms its commitment to international cooperation and the 
purposes and principles of the Charter of the United Nations, welcomes initiatives of 
the United Nations to address the global challenge of COVID-19, including through 
the implementation of the 2030 Agenda for Sustainable Development, and in this 
__________________ 






regard recalls the thirty-first special session of the General Assembly, convened in 
response to the COVID-19 pandemic. 
3. The Commission recognizes the dramatic consequences of the COVID-19 
pandemic on all aspects of the world drug problem.  
4. The Commission recalls the commitments of Members States to strengthening 
actions at the national, regional and international levels to accelerate the 
implementation of the joint commitments to address and counter the world drug 
problem, and encourages Member States to continue their efforts, taking into 
consideration the drug-related consequences of the pandemic. 
5. The Commission reiterates its commitment to respecting, protecting and 
promoting all human rights, fundamental freedoms and the inherent dignity of all 
individuals and the rule of law in the development and implementation of drug 
policies, including in its responses to the COVID-19 pandemic. 
6. The Commission recognizes and supports the efforts of law enforcement 
authorities and members of security forces in the fight against drug trafficking and 
related crimes, noting that their sustained efforts during the COVID-19 pandemic, 
often undertaken at great risk to their health and that of their families, have resulted 
in increases in arrests, seizures of drugs and property and the freezing of assets.  
7. The Commission submits the present statement as a substantive contribution to 
the 2021 high-level political forum on sustainable development, devoted to the main 
theme, “Sustainable and resilient recovery from the COVID-19 pandemic that 
promotes the economic, social and environmental dimensions of sustainab le 
development: building an inclusive and effective path for the achievement of the 2030 
Agenda in the context of the decade of action and delivery for sustainable 
development”, in addition to the contribution that it has already submitted in 2021.  
 
  New trends, challenges and obstacles that the COVID-19 pandemic poses to all 
aspects of the world drug problem 
 
8. The Commission stresses that the pandemic and resulting lockdowns have led 
to the development of new patterns of illicit drug use, such as poly-substance use. 
9. The Commission notes that emerging evidence in some countries suggests that 
people with drug use disorders, including those incarcerated, may be at increased risk 
of more severe illness and mortality from COVID-19 due to underlying health 
conditions, as well as other factors, which may be exacerbated during the pandemic.  
10. The Commission acknowledges that, owing to the nature of the pandemic, the 
traditional demand reduction infrastructure, which often requires in-person 
engagement, faces increasing challenges in providing prevention, early intervention, 
treatment, care, recovery, rehabilitation, and social reintegration measures, as well as 
measures aimed at minimizing the adverse public health and social consequences of 
drug abuse, at least at the same level as provided before the COVID-19 pandemic. 
11. The Commission notes with concern that, owing to challenges that health 
systems face because of the COVID-19 pandemic, the capacity of drug treatment and 
health services may be affected, potentially causing an increase in deaths related to 
drug use. 
12. The Commission notes with concern the difficulties encountered by Member 
States in ensuring the continued access to and availability of internationally controlled 
substances for medical and scientific purposes throughout the world, and appreciates 
the work of the International Narcotics Control Board and the United Nations Office 
on Drugs and Crime, within their respective mandates, in supporting Member States 
to ensure the access to and availability of such drugs, as well as in raising awareness 
about the problem. 
13. The Commission encourages Member States to continue to address barriers to 






while preventing their non-medical use or diversion into illicit channels, including 
those related to legislation, regulatory systems, health-care systems, affordability, the 
training of health-care professionals, education, awareness-raising, estimates, 
assessments and reporting, benchmarks for consumption of substances under control, 
and international cooperation and coordination, in particular with a view to ensuring 
improved responses to a possible future pandemic and other emerging threats. 
14. The Commission notes that the COVID-19 pandemic may have initially affected 
the illicit cultivation, production and manufacture of and trafficking in drugs, and may 
have also resulted in new methods of manufacture, distribution and marketing of , and 
trafficking in, some types of drugs.  
15. The Commission recognizes that changes in trafficking routes and methods, 
including increased maritime trafficking and online sales of drugs through both the 
darknet and the surface web, have resulted in new challenges for law enforcement 
authorities. 
16. The Commission notes with concern that, in the pandemic and post-pandemic 
period, there may be funding shortages and diversion of resources away from drug -
related initiatives, including those relating to drug prevention and treatment and 
related health and social services, alternative development and law enforcement.  
17. The Commission recognizes that, in the long term, the COVID-19 pandemic 
may lead to an increase in illicit drug cultivation, production and trafficking and other 
drug-related criminal activities, as well as drug use disorders and related health and 
social consequences. 
 
  Good practices and opportunities  
 
18. The Commission acknowledges that the COVID-19 pandemic has led to the 
development of new and innovative approaches to drug prevention and treatment and 
related health and social services, which may result in enhanced cooperation between 
public health and law enforcement authorities and other relevant stakeholders of 
Member States at the national, regional and international levels.  
19. The Commission notes that, in order to reduce the risk of COVID-19 
transmission associated with in-person services, some health systems have introduced 
or expanded e-health platforms and procedures to prevent drug abuse and provide 
medications, counselling and consultations, including telemedicine, and that these 
innovations may lead to new treatment strategies in future.  
20. The Commission underlines the role of drug treatment and social services, peer 
support and community outreach.  
21. The Commission calls attention to the importance of undertaking systematic 
monitoring, evaluation and data collection in the implementation of new approaches 
to drug prevention, treatment and related health and social services, with a view to 
establishing scientific evidence that these interventions foster the desired effects of 
promoting quality assurance, where appropriate, and to exchanging information in the 
Commission on best practices for these interventions, once scientific evidence for 
their effectiveness has been established, and takes note of the contribution of the 
informal scientific network of the United Nations Office on Drugs and  Crime and the 
World Health Organization in this regard.  
22. The Commission emphasizes the importance of the use of existing online 
database platforms, such as those operated by the United Nations Office on Drugs and 
Crime and the International Narcotics Control Board, for effective and increased 
cooperation among law enforcement and forensic officials in gathering and sharing 






23. The Commission takes note of the United Nations Office on Drugs and Crime 
research brief on COVID-19 and the drug supply chain, 1  as well as the expert 
meetings and webinars organized by relevant international and regional organizations 
on drug related topics, which serve as valuable information exchange platforms.  
24. The Commission acknowledges that increased social distancing and general 
isolation during the COVID-19 pandemic have made the use of private sector 
platforms to market, sell, transport and finance illicit trafficking – a feature of the 
drug trafficking environment for the past several years – a convenient way to purchase 
and deliver drugs, and has increased the need for law enforcement, regulatory and 
other relevant authorities to engage, as appropriate, with the private sector to assist in 
efforts to detect and interdict trafficking, and takes note of the relevant expert group 
meetings convened by, inter alia, the International Narcotics Control Board on these 
topics. 
25. The Commission recognizes the important role of the scientific community, 
academia, civil society, in particular non-governmental organizations, and the private 
sector in contributing to the efforts of Member States to address and counter the world 
drug problem, including in the context of the COVID-19 pandemic. 
 
  Actions to take 
 
26. The Commission stresses that addressing and countering the world drug problem 
require coordinated multidisciplinary efforts and that such efforts should become a 
top priority in the post-COVID-19 period. 
27. The Commission encourages Member States to consider expanding the coverage 
of and strengthening drug prevention and treatment systems and related health and 
social services to increase their resilience in order to respond effectively to possible 
future pandemics and other emerging health threats.  
28. The Commission encourages Member States and relevant stakeholders, within 
their national contexts, to continue to develop and implement innovative drug 
treatment and recovery delivery systems, such as e-health platforms and procedures, 
in the post-pandemic environment in order to promote efficient, accessible and 
durable opportunities for treatment and recovery, where applicable.  
29. The Commission encourages national, regional and international efforts to 
promote viable economic alternatives, in particular  for communities affected by or at 
risk of the illicit cultivation, manufacture, production of and trafficking in drugs, as 
well as other illicit drug-related activities in urban and rural areas, including through 
comprehensive alternative development programmes, in particular with reference to 
the United Nations Guiding Principles on Alternative Development, 2 which may help 
to mitigate any negative economic consequences of the COVID-19 pandemic. 
30. The Commission invites Member States, subject to the availability of resources, 
to further strengthen measures, strategies, and inter-agency and international 
cooperation and partnerships, to ensure the access to and availability of controlled 
substances for medical and scientific purposes, which may improve responses to 
future emergencies, including emergency medical care situations.  
31. The Commission encourages Member States to expand law enforcement 
activities targeting trafficking modalities that have emerged or increased in the 
context of COVID-19 and to increase coordination between Member States.  
32. The Commission encourages all Member States to continue to prevent and 
counter the diversion of and trafficking in precursors and pre-precursors for illicit use, 
during the COVID-19 pandemic and beyond. 
__________________ 
 1 United Nations Office on Drugs and Crime, “COVID-19 and the drug supply chain: from 
production and trafficking to use”, Research Brief (Vienna, 2020).  






33. The Commission urges Member States to strengthen bilateral, regional and 
international cooperation to counter the exploitation by drug traffickers of traditional 
and online trafficking methods and routes during the COVID-19 pandemic and 
beyond. 
34. The Commission calls upon Member States to enhance, including during the 
COVID-19 pandemic, access to treatment for drug use disorders for those 
incarcerated and to promote effective oversight in that regard.  
35. The Commission notes that the principle of common and shared responsibility 
should remain at the core of international cooperation on all aspects of the world drug 
problem. 
36. The Commission commits itself to promoting the provision of technical 
assistance and capacity-building to Member States, upon request, in particular those 
most affected by the COVID-19 pandemic, in addressing and countering the world 
drug problem. 
37. The Commission invites the United Nations Office on Drugs and Crime, as the 
leading entity in the United Nations system for addressing and countering the world 
drug problem, in coordination with relevant United Nations entities and other 
international organizations, within their respective mandates, to conduct research and 
collect data on the impact of the COVID-19 pandemic on the world drug problem, 
and to regularly inform the Commission about progress made in that regard.  
38. The Commission invites Member States and the International Narcotics Control 
Board, within its treaty-mandated functions, to continue further developing their 
dialogue, including through regular consultations and the Board’s country missions, 
to lend assistance to Member States in their efforts to effectively implement the three 
international drug control conventions.  
39. The Commission invites Member States and other relevant stakeholders to 
share, through the Commission, national good practices and lessons learned to 
improve national drug policies, so that Member States are able to more quickly 
respond to a possible future global pandemic and other emerging threats. 
40. The Commission urges Member States to ensure that no one affected by the 
world drug problem is left behind in the health response to the COVID-19 pandemic 
and in efforts to mitigate the drug-related consequences of the pandemic.  
41. The Commission commits itself to giving due attention to the impact of the 
COVID-19 pandemic during its thematic discussions in 2021 on the implementation 
of all international drug policy commitments, as follow-up to the Ministerial 
Declaration on Strengthening Our Actions at the National, Regional and International 
Levels to Accelerate the Implementation of Our Joint Commitments to Address and 
Counter the World Drug Problem3 of 2019. 
42. The Commission welcomes the efforts made by Member States to comply with 
the provisions of the three international drug control conventions and other relevant 
international instruments and to ensure their effective implementation, despite the 
challenges posed by the COVID-19 pandemic. 
43. The Commission encourages Member States to accelerate the implementation 
of all international drug policy commitments so that the progress made in addressing 
and countering all aspects of the world drug problem at the national, regional and 
global levels is maintained and continued in the context of the COVID-19 pandemic 




 3 See Official Records of the Economic and Social Council, 2019, Supplement No. 8 (E/2019/28), 
chap. I, sect. B.  
